Compare ARVN & EH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARVN | EH |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 658.2M | 679.5M |
| IPO Year | 2018 | 2019 |
| Metric | ARVN | EH |
|---|---|---|
| Price | $7.57 | $7.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 3 |
| Target Price | $15.05 | ★ $22.47 |
| AVG Volume (30 Days) | 694.3K | ★ 1.4M |
| Earning Date | 05-04-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | N/A | $33.23 |
| Revenue Next Year | N/A | $73.83 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.06 | $6.50 |
| 52 Week High | $14.22 | $20.44 |
| Indicator | ARVN | EH |
|---|---|---|
| Relative Strength Index (RSI) | 37.96 | 37.09 |
| Support Level | $7.35 | N/A |
| Resistance Level | $10.18 | $10.58 |
| Average True Range (ATR) | 0.42 | 0.68 |
| MACD | 0.05 | -0.16 |
| Stochastic Oscillator | 31.43 | 15.17 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
EHang Holdings Ltd is an urban air mobility (UAM) technology platform company. It focuses on making safe, autonomous, eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with unmanned aerial vehicle (UAV) systems and solutions: air mobility (including passenger transportation and logistics), smart city management, and aerial media solutions. EHang's EH216-S has received a production certificate and standard airworthiness certificate for passenger-carrying pilotless eVTOL aircraft issued by the Civil Aviation Administration of China. The group continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.